NHS to Offer Improved Stop Smoking Pill in England

Nov.15.2024
NHS to Offer Improved Stop Smoking Pill in England
NHS will start offering an "improved" stop smoking pill to tens of thousands of people in England who want to quit cigarettes.

According to a recent report by the BBC, the National Health Service (NHS) in the UK will begin offering an "improved" stop smoking pill to tens of thousands of people in England who are looking to quit smoking.

 

The NHS has stated that Varenicline is as effective as e-cigarettes and more effective than nicotine replacement gum or patches.

 

This medication can suppress nicotine addiction and was previously marketed under the brand name Champix on the NHS several years ago. However, it was withdrawn due to some impurity issues. The new version has now been approved as safe.

 

Officials stated that e-cigarettes are sometimes provided, typically by local NHS stop smoking services, with an initial e-cigarette starter kit provided for approximately two weeks.

 

Varenicline is a prescription medication, which means people cannot purchase it over the counter at a pharmacy or supermarket and instead need to see their general practitioner (GP) or NHS stop smoking service to obtain it. It works by reducing cravings for nicotine and blocking its effects on the brain, while also helping to alleviate withdrawal symptoms such as irritability or difficulty sleeping.

 

The NHS states that it has been proven to help approximately one quarter of people quit smoking for at least six months when used in conjunction with behavioral support, such as counseling. The study suggests that this could help over 85,000 people quit smoking each year and potentially prevent around 9,500 smoking-related deaths in the next five years.

 

Health and Social Care Secretary Wes Streeting said: "The rollout of this pill can save the NHS millions of pounds, save appointments to help other patients be seen faster and save lives."

 

NHS CEO Amanda Pritchard announced at the annual NHS Providers conference that this drug could be a "game-changer" for those looking to quit smoking.

 

Due to e-cigarettes not being licensed as medication, general practitioners are unable to prescribe e-cigarettes for individuals attempting to quit smoking unless approved by the local NHS. However, some local governments do indeed provide e-cigarettes for smokers wanting to quit.

 

The guidelines suggest that people first try to obtain licensed smoking cessation medications, even though e-cigarettes are recognized as a smoking cessation aid. The harms of e-cigarettes are far less than smoking.

 

However, health experts unanimously agree that people should not start using e-cigarettes unless it is for smoking cessation.

 

Hazel Cheeseman, chief executive of Action on Smoking and Health, said access to services was variable.

 

"Wherever a smoker lives, they should be able to access the most effective forms of treatment to help them stop," she said.

 

"Improving access to varenicline will be a positive step forward to help prevent the tens of thousands of deaths caused by smoking. However, a drug alone will not transform smoking rates. Services are needed to support smokers and prescribe these products."

 

"The NHS has done a good job in setting up in-hospital support to help people quit smoking, which complements the services provided in the community, said Hazel Cheeseman. "But gaps remain around the country, with services often in peril as local NHS organizations try to balance the books."

 

Minnesota Sues Loon as State Enforcement Targets U.S. Vape Brand Operators
Minnesota Sues Loon as State Enforcement Targets U.S. Vape Brand Operators
Minnesota Attorney General Keith Ellison sued Maduro Distributors, Inc., doing business as Loon, on July 15, 2026, alleging that the company illegally manufactured, distributed and sold flavored vapes that appeal to minors.
Jul.16
Alaska Warns 1,500 Tobacco Retailers Over Unauthorized Vapes and Nicotine Pouches
Alaska Warns 1,500 Tobacco Retailers Over Unauthorized Vapes and Nicotine Pouches
Alaska Attorney General Stephen J. Cox has sent notices to more than 1,500 tobacco retailers and distributors warning them against selling vape and nicotine pouch products that lack authorization from the U.S. Food and Drug Administration (FDA). According to the Alaska Department of Law, businesses were advised to verify products against FDA authorization databases and avoid selling unauthorized nicotine products. The action highlights how state-level enforcement is increasingly extending federal product authorization requirements to retail channels.
Jul.24
Seita’s Julia Neumaier Says France Should Target Vape Access, Not Plain Packaging
Seita’s Julia Neumaier Says France Should Target Vape Access, Not Plain Packaging
Julia Neumaier, general manager of Seita, Imperial Brands’ French subsidiary, said France should focus vaping regulation on access control, age verification, online sales and distribution channels, rather than applying tobacco-style plain packaging to vaping products.
Jul.15
South Korea’s New Vape Rules Raise Bar for E-Liquid Makers and China-Linked Supply Chains, Expert Says
South Korea’s New Vape Rules Raise Bar for E-Liquid Makers and China-Linked Supply Chains, Expert Says
South Korea’s new vape regulations are reshaping the e-liquid market, raising compliance requirements for manufacturers, retailers and overseas suppliers. In an interview with 2Firsts, Korean nicotine products specialist Sam Kim discusses licensing barriers, inventory impacts, China-linked supply chains, and emerging regulatory challenges around nicotine analogues, nicotine-free products and DIY mixing. The Korean case may offer broader insights as governments worldwide adapt to rapidly evolving nicotine products.
Jul.16
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
In an interview with Romanian marketing publication IQads, Marek Gębski, Director of Smoke-Free Products at Philip Morris Romania, said IQOS experience spaces are evolving from traditional retail locations into platforms for consumer engagement and brand connection. Through locations such as IQOS Boutique Victoriei, PMI aims to use design, culture and consumer experiences to strengthen communication with adult consumers about smoke-free products. The interview highlights how tobacco companies are expanding smoke-free strategies beyond products toward experiential marketing and consumer relationships.
Aug.11